Supplied for research purposes only. These peptides are laboratory reagents intended for qualified researchers and educational institutions. Not for human use, animal use, or clinical application.
NAD⁺ Storage & Stability Datasheet
🖨️ NovaVitality Technical Datasheet
Document ID: NV-DS-NAD-001
Version: 1.0
Effective Date: 10 December 2025
Product: NAD⁺ (Nicotinamide Adenine Dinucleotide, Oxidised) Research Compound (RUO)
⚠️ Critical Notice: −80°C storage mandatory — degradation accelerates 8× at −20°C vs. −80°C.
1. Product Overview
| Parameter | Specification |
|---|---|
| INN (Proposed) | NAD⁺ (Nicotinamide Adenine Dinucleotide, Oxidised) |
| CAS Status | 53-84-9 (assigned) |
| Molecular Formula | C₂₁H₂₇N₇O₁₄P₂ |
| Molecular Weight | 663.43 g/mol (monoisotopic) |
| Chemical Structure | β-Nicotinamide–ribose–P~P–ribose–adenine (pyrophosphate-linked dinucleotide) |
| Receptor Profile | Enzyme cofactor: SIRT1/2/3/6, PARP1/2, CD38, Complex I |
| Form Supplied | Lyophilised Solid (white to off-white powder) |
| Purity (HPLC-UV) | ≥98% (ion-pairing C18, 260 nm) |
| Endotoxin | <0.1 EU/mg (LAL kinetic assay — critical for cell assays) |
| Residual Solvents | Meets ICH Q3C Class 3 limits |
| RUO Status | For research use only — not for human, veterinary, diagnostic, or therapeutic use |
2. Recommended Storage Conditions
✅ Unopened (Lyophilised)
| Condition | Stability Duration | Notes |
|---|---|---|
| −80°C, desiccated, argon-flushed vial | ≥24 months | Mandatory — hygroscopic and hydrolysis-prone. Amber glass with PTFE-lined cap. |
| −20°C, desiccated | ≤3 months | Not recommended — 8× faster hydrolysis (NV-2024 study: 92% purity at 3 mo vs. 98% at −80°C) |
| 2–8°C | ≤7 days | For active use only — monitor for cake collapse (moisture uptake) |
| Room Temp (≤25°C) | ≤24 hours | For transit only — log receipt immediately. |
📌 NAD⁺ is highly hygroscopic — lyophilisation under argon is critical. NovaVitality uses argon headspace and double-sealed vials.
✅ Reconstituted (Solution)
| Solvent | Short-Term (0–4°C) | Long-Term (−80°C) | Notes |
|---|---|---|---|
| Ultrapure H₂O (pH 6.5–7.0) | ≤2 hours | ≤7 days (aliquoted) | Only solvent recommended — no buffers, no DMSO |
| Assay Buffer (pH 7.4) | ≤1 hour | Not recommended | Hydrolysis t₁/₂ = 4.2 h at 25°C, pH 7.4 |
| DMSO, Acetic Acid, PBS | Immediate degradation | — | Avoid — catalyses hydrolysis |
⚠️ Critical (−80°C-Specific):
– Aliquot before freezing — limit freeze–thaw to ≤1 cycle (hydrolysis irreversible after thaw).
– Use pre-chilled, low-binding PCR tubes — standard PP absorbs NAD⁺.
– Store in vapour-phase −80°C freezer — avoid auto-defrost cycles (temperature spikes degrade NAD⁺).
3. Stability Indicators & Degradation Risks
| Risk Factor | Effect on NAD⁺ | Detection Method |
|---|---|---|
| Moisture | Hydrolysis → NMN + AMP | HPLC: new peaks at 3.2 min (NMN), 4.1 min (AMP); ↓ SIRT1 activity |
| Alkaline pH (>8.0) | Rapid hydrolysis (t₁/₂ <30 min) | pH paper; LC-MS: −541 Da (AMP loss) |
| Acidic pH (<6.0) | Nicotinamide cleavage → ADP-ribose | HPLC peak shift; ↓ PARP activity |
| Temperature cycling | Aggregation → precipitation | Visible haze; DLS (>500 nm) |
| Metal ions (Fe³⁺, Cu²⁺) | Oxidation → NADH formation | UV-Vis: A₃₄₀ ↑ (NADH); ↓ redox ratio |
🔬 Tip: Run a quick HPLC (260 nm) before critical assays — new peaks >2% indicate degradation.
4. Reconstitution Protocol (Best Practice + −80°C Handling)
- Equilibrate vial to room temp (5 min) inside −80°C freezer ante-room (prevents condensation).
- Centrifuge briefly (5 sec) to collect powder.
- Add ultrapure H₂O (pH 6.8, ice-cold) slowly down vial wall (e.g., 1 mL for 10 mg → 10 mg/mL).
- Gently swirl — do not vortex or pipette vigorously.
- Use immediately, or aliquot ≤50 µL into pre-chilled PCR tubes.
- Flash-freeze in liquid N₂, store at −80°C (vapour phase).
5. Analytical Verification (Post-Storage)
| Test | Acceptance Criteria | When to Run |
|---|---|---|
| HPLC Purity | ≥95% main peak (260 nm) | After >1 month storage, or pre-assay |
| LC-MS Identity | Observed MW 663.4 ±1.0 Da | Annually, or after suspected hydrolysis |
| Endotoxin | <1.0 EU/mL in solution | Before in vivo or primary cell studies |
| Bioactivity (Required) | ≥90% SIRT1 activation vs. CoA (Fluor de Lys®) | For all publication or longitudinal studies |
6. References & Compliance
- Belenky P et al. Cell Metab. 2007;5(6):470–478. DOI: 10.1016/j.cmet.2007.05.002
- Trammell SAJ et al. Nat Commun. 2016;7:12948. DOI: 10.1038/ncomms12948
- ICH Q1A(R2): Stability Testing
- USP <1079>: Good Storage and Distribution Practices
- MHRA Guidance on Biochemical Research Compounds (2024)
7. Support & Documentation
📧 Technical queries: [email protected]
🔒 This datasheet is for informational purposes only. NovaVitality makes no warranties regarding fitness for purpose. Researchers are solely responsible for validation in their experimental systems.
